SPY412.27-3.80 -0.91%
DIA338.12-3.18 -0.93%
IXIC13,818.41-131.81 -0.94%

BRIEF-Sage Therapeutics Announces Continued Positive Zuranolone Data For Both 30 Mg And 50 Mg Doses In Open-Label Shoreline Study In Patients With Mdd

· 03/17/2021 06:32
BRIEF-Sage Therapeutics Announces Continued Positive Zuranolone Data For Both 30 Mg And 50 Mg Doses In Open-Label Shoreline Study In Patients With Mdd

- SAGE Therapeutics Inc SAGE.O:

  • SAGE THERAPEUTICS ANNOUNCES CONTINUED POSITIVE ZURANOLONE DATA FOR BOTH 30 MG AND 50 MG DOSES IN OPEN-LABEL SHORELINE STUDY IN PATIENTS WITH MDD

  • SAGE THERAPEUTICS - IN 30 MG & 50 MG COHORTS, ZURANOLONE WAS GENERALLY WELL-TOLERATED WITH ADVERSE EVENT PROFILE CONSISTENT WITH DATA REPORTED EARLIER

  • SAGE THERAPEUTICS INC - PLANS TO REPORT ADDITIONAL DATA FROM PATIENTS IN 50 MG DOSE COHORT IN LATE 2021

Source text for Eikon: ID:nBw5n682Wa

Further company coverage: SAGE.O


((reuters.briefs@thomsonreuters.com;))